Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Jul 7. pii: aww173. [Epub ahead of print]

PMID:
27401521
2.

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Jun 13. pii: jnnp-2016-313760. doi: 10.1136/jnnp-2016-313760. [Epub ahead of print]

PMID:
27298148
3.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group.

Ann Neurol. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1.

PMID:
27145331
4.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

5.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2016 Apr 7. pii: 1352458516643392. [Epub ahead of print]

PMID:
27055805
6.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10.

7.

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.

Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group.

Eur J Neurol. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19.

PMID:
26782663
8.

Defining reliable disability outcomes in multiple sclerosis.

Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H.

Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.

PMID:
26359291
9.

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.

Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group.

Mult Scler. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21.

PMID:
26199347
10.

Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.

Schipper HM, Arnold D, GrandʼMaison F, Melmed C, Moore F, Levental M, Su H, Constantin M, Stril JL, Godin J.

Clin Neuropharmacol. 2015 Jul-Aug;38(4):127-31. doi: 10.1097/WNF.0000000000000090.

PMID:
26166235
11.

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.

Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J.

PLoS One. 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. eCollection 2015.

12.

Predictors of disability worsening in clinically isolated syndrome.

Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M.

Ann Clin Transl Neurol. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27.

13.

BREMSO: a simple score to predict early the natural course of multiple sclerosis.

Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M.

Eur J Neurol. 2015 Jun;22(6):981-9. doi: 10.1111/ene.12696. Epub 2015 Mar 25.

PMID:
25808578
14.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

PMID:
25665031
15.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group.

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

PMID:
25546031
16.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.

Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group.

Mult Scler. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5.

PMID:
25480857
17.

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H.

Ann Neurol. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20.

PMID:
25283272
18.

Risk of relapse phenotype recurrence in multiple sclerosis.

Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group.

Mult Scler. 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28.

PMID:
24777276
19.

Fingolimod after natalizumab and the risk of short-term relapse.

Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group.

Neurology. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7.

20.

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β.

Larochelle C, Grand'maison F, Bernier GP, Latour M, Cailhier JF, Prat A.

Mult Scler. 2014 Nov;20(13):1783-7. doi: 10.1177/1352458514523692. Epub 2014 Feb 17.

PMID:
24534079
Items per page

Supplemental Content

Loading ...
Write to the Help Desk